This result in concordance to a previously published meta-analysis comprising seven randomized controlled trials, in which immune checkpoint blockade had resulted in significantly better PFS and OS as compared to chemotherapy in EGFR wild-type stage IV NSCLC patients (PFS: HR 0.83, 95% CI 0.73-0.95); OS: HR 0.67, 95% CI 0.60-0.76; p<00001) (46). Here, EGFR is linked to non-small cell lung carcinoma.